Athira Pharma (ATHA) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ATHA Stock Alerts $1.93 -0.08 (-3.98%) (As of 11:56 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineOne Athira Pharma Insider Raised Their Stake In The Previous Yearfinance.yahoo.com - April 23 at 10:45 AMAthira Pharma (ATHA) Price Target Increased by 7.49% to 7.57msn.com - April 17 at 8:48 AMAthira Pharma, Inc.: Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officerfinanznachrichten.de - April 15 at 10:36 AMAthira Pharma Appoints Javier San Martin As New Chief Medical Officermarkets.businessinsider.com - April 15 at 10:36 AMAthira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officerglobenewswire.com - April 15 at 7:00 AMAthira Pharma, Inc.: Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Diseasefinanznachrichten.de - April 11 at 10:16 AMAthira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Diseasefinance.yahoo.com - April 11 at 10:16 AMAthira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Diseaseglobenewswire.com - April 11 at 7:00 AMAthira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meetingglobenewswire.com - April 3 at 7:00 AMAthira Pharma, Inc. (ATHA)finance.yahoo.com - March 20 at 6:43 PMShort Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Increases By 20.5%marketbeat.com - March 15 at 9:37 AMAthira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conferencefinance.yahoo.com - March 8 at 8:45 AMAthira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conferenceglobenewswire.com - March 8 at 7:00 AMShort Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Drops By 9.4%marketbeat.com - March 3 at 10:26 AMNan Fung Group Holdings Ltd Purchases 168,231 Shares of Athira Pharma, Inc. (NASDAQ:ATHA)marketbeat.com - February 25 at 10:29 AMAthira Pharma, Inc.: Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updatesfinanznachrichten.de - February 23 at 6:49 AMAthira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updatesglobenewswire.com - February 22 at 4:05 PMBarclays PLC Raises Holdings in Athira Pharma, Inc. (NASDAQ:ATHA)marketbeat.com - February 22 at 4:14 AMAthira Pharma, Inc. (NASDAQ:ATHA) Sees Significant Increase in Short Interestmarketbeat.com - February 13 at 12:33 PMAthira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)finance.yahoo.com - February 8 at 8:29 PMAthira Pharma Inc (ATHA)uk.investing.com - February 6 at 3:53 AMShort Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Grows By 25.4%marketbeat.com - January 28 at 4:40 AMWith 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investorsfinance.yahoo.com - January 22 at 10:18 AMAthira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 16.6% in Decembermarketbeat.com - January 15 at 10:53 PMAthira Pharma: A Buy Rating Backed by Promising Alzheimer’s Drug Prospects and Strong Cash Positionmarkets.businessinsider.com - January 11 at 9:49 AMAthira Pharma's chief medical officer retiresbizjournals.com - January 10 at 7:52 AMMark James Litton Sells 4,820 Shares of Athira Pharma, Inc. (NASDAQ:ATHA) Stockmarketbeat.com - January 8 at 6:33 PMBTIG Reaffirms Their Buy Rating on Athira Pharma (ATHA)markets.businessinsider.com - January 8 at 8:11 AMAthira Pharma Provides 2024 Clinical Pipeline Outlook and Business Updatefinance.yahoo.com - January 8 at 8:11 AMBuy Rating Affirmed for Athira Pharma as LIFT-AD Trial Progresses with Promising Prospects and Solid Financial Standingmarkets.businessinsider.com - January 4 at 9:56 AMAthira Pharma, Inc.: Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Diseasefinanznachrichten.de - January 3 at 8:04 AMAthira Pharma 10% owner Perceptive Advisors discloses purchase of 605,686 sharesmsn.com - January 2 at 3:23 PMAthira Pharma Stock (NASDAQ:ATHA) Dividends: History, Yield and Datesbenzinga.com - December 25 at 11:46 PMOptimistic Outlook for Athira Pharma Despite Setback: Buy Rating Affirmedmarkets.businessinsider.com - December 15 at 8:57 PMBuy Rating for Athira Pharma Backed by Promising Fosgonimeton Trial Results and Favorable Safety Profilemarkets.businessinsider.com - December 13 at 8:29 AMAthira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodiesfinance.yahoo.com - December 12 at 10:32 AMThese biotechs targeting multiple neurodegenerative diseases (ATHA)marketbeat.com - December 1 at 8:14 AMAthira Pharma to Participate in Sidoti December Small Cap Investor Conferencefinance.yahoo.com - November 29 at 8:53 AMAthira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MNDfinance.yahoo.com - November 28 at 9:50 AMAthira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Diseasefinance.yahoo.com - November 15 at 12:29 PMAthira Pharma Insiders Placed Bullish Bets Worth US$556.3kfinance.yahoo.com - November 15 at 7:29 AMPromising Progress and Robust Funding Drive Buy Rating for Athira Pharmamarkets.businessinsider.com - November 10 at 8:48 PMAthira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updatesfinance.yahoo.com - November 9 at 8:34 PMAthira Pharma to Participate in Jefferies London Healthcare Conferencefinance.yahoo.com - November 8 at 8:33 AMAthira Pharma Inc Ordinary Shares ATHAmorningstar.com - November 5 at 7:31 PMBuy Rating for Athira Pharma: Fosgo’s Unique Approach and Promising Trials Bolster Investment Appealmarkets.businessinsider.com - October 30 at 8:11 PMAthira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)finance.yahoo.com - October 5 at 6:09 PMAthira Pharma to Participate in Upcoming October Conferencesfinance.yahoo.com - September 28 at 9:18 AMAthira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conferencefinance.yahoo.com - September 19 at 8:41 AMAthira Pharma Stock (NASDAQ:ATHA) Earnings Dates and Earning Callsbenzinga.com - September 8 at 4:52 PM Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers. Find out what it is and see how you can get in with just a few dollars. ATHA Media Mentions By Week ATHA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHA News Sentiment▼0.000.44▲Average Medical News Sentiment ATHA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHA Articles This Week▼11▲ATHA Articles Average Week Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATRA News Today CVM News Today PLX News Today ALVR News Today PASG News Today GRTS News Today CGTX News Today DTIL News Today CRIS News Today LGST News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
